European Commission Grants Orphan Drug Designation for Vivet Therapeutics Gene Therapy Product for the Treatment of Cerebrotendinous Xanthomatosis

Vivet Therapeutics France United Kingdom United States of America

Pre-clinical data of VTX-806 in mice demonstrated normalization of metabolic parameters in blood and brain, and of upregulated compensatory enzymesEUR 4.9 million funding provided by French Government to develop VTX-806 as an effective treatment option to stabilize or reverse symptoms in CTX patients- Follow us on LinkedIn @Vivet Therapeutics and Twitter @Vivet_tx.

View original content:https://www.prnewswire.co.uk/news-releases/european-commission-grants-orphan-drug-designation-for-vivet-therapeutics-gene-therapy-product-for-the-treatment-of-cerebrotendinous-xanthomatosis-ctx-302238650.html